New trials, publications, preprints and grants on this target, month by month.
Trial
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
1 Feb 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
27 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Frequent FLT3 and IDH co-mutations in acute myeloid leukemia with mutated NPM1, NUP98 rearrangement, and KMT2A partial tandem duplication but not rearrangement: potential for combined targeted therapy.
5 Nov 2026· Haematologica· PUBMED
Publication
Distinct clinical and molecular profiles of acute myeloid leukemia defined by mutations in IDH1, IDH2, and TET2.
5 Nov 2026· Haematologica· PUBMED
Publication
Measurable Residual Disease in IDH-Mutated AML: Identifying a Clinically Relevant Threshold for IDH Mutation Monitoring.
2 Nov 2026· European journal of haematology· PUBMED
Trial
Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
1 Nov 2026· PHASE2 · RECRUITING· CTGOV
Publication
Deep learning predicts IDH1 mutation status in acute myeloid leukemia from bone marrow smears.
29 Oct 2026· NPJ precision oncology· PUBMED
Publication
IDH2 p.R172 mutation Predicts Superior Outcomes in IDH-mutated Acute Myeloid Leukemia or Myelodysplastic Syndrome patients undergoing Allogeneic Hematopoietic Cell Transplantation: a retrospective study from the Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC).
28 Oct 2026· Transplantation and cellular therapy· PUBMED
Publication
Contrasting molecular and pharmacodynamic signatures of response and resistance to sequential bortezomib and temozolomide in recurrent IDH-wildtype glioblastoma and grade 4 IDH-mutant astrocytoma: an exploratory interim analysis of NCT03643549 phase IB/II trial.
27 Oct 2026· Biomarker research· PUBMED
Publication
Dynamics of IDH1 Mutation and Protein Expression Between Primary and Recurrent Gliomas and Their Prognostic Significance.
27 Oct 2026· Human mutation· PUBMED
Publication
Therapy-related T-lymphoblastic lymphoma following acute myeloid leukemia remission with IDH2 mutation persistence.
16 Oct 2026· Leukemia research reports· PUBMED
Publication
A spectrum of tumorigenesis in an IDH1-mosaic patient with Ollier disease, acute myeloid leukaemia, and parathyroid adenoma.
9 Oct 2026· Frontiers in genetics· PUBMED
Publication
Genome-wide CRISPR screen identifies PKMYT1 inhibition as a synthetic lethal vulnerability in IDH1-mutant glioma.
8 Oct 2026· Cancer letters· PUBMED
Publication
[18F]FET uptake in diffuse lower-grade IDH-mutant glioma correlates with glioma-related epilepsy.
1 Oct 2026· Journal of neuro-oncology· PUBMED
Publication
Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.
23 Sept 2026· Journal of clinical medicine· PUBMED
Publication
Autophagy inhibition sensitizes radiotherapy responses in high-grade mutant IDH1 glioma.
18 Sept 2026· Nature communications· PUBMED
Publication
Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype specific phenotypes.
17 Sept 2026· Neuro-oncology· PUBMED
Publication
Exploration of Bacopa monnieri-derived Green Ligands for Targeted IDH1 Inhibition in Glioblastoma.
16 Sept 2026· Current drug discovery technologies· PUBMED
Publication
Spatial analysis reveals the evolving organization of IDH-mutant glioma.
14 Sept 2026· Cancer cell· PUBMED
Publication
APOBEC3 activity and DNA polymerase-ε deficiency are associated with distinct IDH1 R132 hotspot mutations.
9 Sept 2026· Molecular oncology· PUBMED
Publication
Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.
9 Sept 2026· Journal of neuro-oncology· PUBMED
Publication
Histopathologic, Genomic, and Clinical Characteristics of Primary Cutaneous Melanocytic Tumors With Concomitant NRAS Q61 and IDH1 R132C Mutations.
8 Sept 2026· Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc· PUBMED
Publication
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models.
3 Sept 2026· Blood cancer discovery· PUBMED
Publication
Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome.
3 Sept 2026· Haematologica· PUBMED
Publication
Metabolomic and lipidomic profiling reveals distinct subtypes of glioblastoma IDH-wildtype and shared metabolic features with astrocytoma IDH-mutant grade 4.
2 Sept 2026· Neuro-oncology advances· PUBMED
Trial
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
1 Sept 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.
1 Sept 2026· Neuro-oncology· PUBMED
Publication
Targeting IDH-driven Oncometabolism in glioblastoma: a computational approach for the identification of potential inhibitors.
26 Aug 2026· Frontiers in bioinformatics· PUBMED
Publication
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
26 Aug 2026· British journal of haematology· PUBMED
Publication
Ivosidenib monotherapy in IDH1 mutated myelodysplastic neoplasm/syndrome.
25 Aug 2026· Leukemia· PUBMED